David Joseph Gaffin, an officer of Alkermes plc., filed a Form 144 notice of proposed sale on November 3, 2026, covering 2,035 shares of Alkermes common stock with an aggregate market value of $93,955.95.

Key Highlights

  • Proposed sale: Gaffin intends to sell 2,035 shares of Alkermes common stock through Merrill Lynch, located at 225 Liberty Street, Floor 37, New York, NY 10281.
  • Aggregate market value: The shares proposed for sale carry an aggregate market value of $93,955.95, according to the filing.
  • Shares outstanding: The filing states 168,043,540 shares of Alkermes common stock were outstanding at the time of notice.
  • Source of shares: The shares to be sold were acquired through vesting of restricted stock unit awards from Alkermes plc. on May 21, 2015 (769 shares), May 21, 2016 (844 shares), and March 3, 2017 (422 shares), all granted as part of the issuer's equity compensation plan.
  • 10b5-1 plan: The filing indicates a Rule 10b5-1 trading plan or instruction was adopted on November 19, 2025.
  • Approximate date of sale: The proposed sale is dated November 3, 2026, on NASDAQ.
  • Recent sales history: Gaffin sold 2,034 shares on each of five prior occasions between June 4, 2026, and October 2, 2026, generating gross proceeds ranging from $83,455.02 to $109,897.02 per transaction.

Alkermes Officer Gaffin's Proposed Share Sale and Prior Transaction History

According to the Form 144 filed with the U.S. Securities and Exchange Commission on November 3, 2026, David Joseph Gaffin, identified as an officer of Alkermes plc. (NASDAQ:ALKS), proposes to sell 2,035 shares of the company's common stock. The filing lists Merrill Lynch at 225 Liberty Street, Floor 37, New York, NY 10281, as the broker for the proposed transaction. The aggregate market value of the shares to be sold is listed as $93,955.95, with 168,043,540 total shares outstanding at the time of the notice.

The shares proposed for sale originated from restricted stock unit award vestings under Alkermes plc.'s equity compensation plan. Specifically, the filing reports 769 shares vested on May 21, 2015, 844 shares on May 21, 2016, and 422 shares on March 3, 2017, with payment for each noted as the respective vesting date. The filing states that a Rule 10b5-1 trading plan or instruction was adopted on November 19, 2025.

The filing also discloses five sales of Alkermes common stock by David Gaffin during the three months prior to the notice. Each of those sales involved 2,034 shares, occurring on June 4, 2026 (gross proceeds: $87,563.70), July 6, 2026 ($109,897.02), August 3, 2026 ($98,811.72), September 3, 2026 ($97,652.34), and October 2, 2026 ($83,455.02). The issuer's address is listed as Connaught House, 1 Burlington Road, Dublin 4, Ireland.

What Was Disclosed

Alkermes officer David Joseph Gaffin filed a Form 144 on November 3, 2026, disclosing a proposed sale of 2,035 shares of common stock with an aggregate market value of $93,955.95, acquired through equity compensation plan vestings, with five prior sales of 2,034 shares each reported over the preceding three months.